Salih J Wakil

US Patent:

6734337, May 11, 2004

Filed:

Aug 14, 2001

Appl. No.:

09/929575

Inventors:

Salih J. Wakil - Houston TX
Martin Matzuk - Pearland TX
Lutfi Abu-Elheiga - Houston TX

Assignee:

Research Development Foundation - Carson City NV

International Classification:

G01N 3300

US Classification:

800 3, 800 8, 800 18

Abstract:

The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of fatty acid oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.

US Patent:

8207196, Jun 26, 2012

Filed:

Feb 1, 2008

Appl. No.:

12/024530

Inventors:

Motonari Uesugi - Houston TX, US
Salih J. Wakil - Houston TX, US
Lutfi Abu-Elheiga - Houston TX, US
Qian Mao - Houston TX, US
Shinji Kamisuki - Kyoto, JP
Akira Kugimiya - Kyoto, JP

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 31/4709
A61K 31/4439
A61K 31/426
A61K 31/4436
A61P 3/10

US Classification:

514314, 514342, 514336, 514365, 548203, 5462704, 5462804, 546172

Abstract:

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

US Patent:

20020104111, Aug 1, 2002

Filed:

Dec 26, 2000

Appl. No.:

09/749109

Inventors:

Salih Wakil - Houston TX, US
Martin Matzuk - Pearland TX, US
Lutfi Abu-Elheiga - Houston TX, US

International Classification:

A01K067/027
C12N005/06

US Classification:

800/018000, 435/354000

Abstract:

The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.

US Patent:

20030028912, Feb 6, 2003

Filed:

Aug 15, 2002

Appl. No.:

10/219871

Inventors:

Martin Matzuk - Pearland TX, US
Lutfi Abu-Elheiga - Houston TX, US
Salih Wakil - Houston TX, US

Assignee:

Research Development Foundation

International Classification:

A01K067/027

US Classification:

800/018000

Abstract:

The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.

US Patent:

20040204338, Oct 14, 2004

Filed:

Jan 16, 2004

Appl. No.:

10/758775

Inventors:

Salih Wakil - Houston TX, US
Lutfi Abu-Elheiga - Houston TX, US
Martin Matzuk - Pearland TX, US

Assignee:

Research Development Foundation

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of fatty acid oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.

US Patent:

20130005768, Jan 3, 2013

Filed:

May 31, 2012

Appl. No.:

13/484685

Inventors:

Motonari Uesugi - Houston TX, US
Salih J. Wakil - Houston TX, US
Lutfi Abu-Elheiga - Houston TX, US
Qian Mao - Houston TX, US
Shinji Kamisuki - Chiba, JP
Akira Kugimiya - Osaka, JP

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 31/4439
C07D 277/24
A61K 31/4709
A61P 3/00
C07D 417/14
C07D 417/04
A61K 31/426

US Classification:

514314, 5462704, 514342, 548203, 514365, 546172

Abstract:

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

US Patent:

20130012538, Jan 10, 2013

Filed:

May 31, 2012

Appl. No.:

13/484702

Inventors:

Motonari Uesugi - Houston TX, US
Salih J. Wakil - Houston TX, US
Lutfi Abu-Elheiga - Houston TX, US
Qian Mao - Houston TX, US
Shinji Kamisuki - Chiba, JP
Akira Kugimiya - Osaka, JP

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 31/4439
A61K 31/4709
A61P 3/06
A61P 3/00
A61P 9/12
A61P 35/00
A61P 9/00
A61K 31/425
A61P 3/10

US Classification:

514314, 514342, 514365

Abstract:

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.

US Patent:

20140038984, Feb 6, 2014

Filed:

Aug 29, 2013

Appl. No.:

14/013918

Inventors:

Motonari Uesugi - Osaka, JP
Salih J. Wakil - Houston TX, US
Mizuki Watanabe - Kyoto, JP

International Classification:

C07D 417/04
C07D 277/24
A61K 31/426
C07D 213/16
A61K 45/06
A61K 31/454
C07D 213/76
A61K 31/496
C07D 235/14
C07D 417/12
A61K 31/4439
A61K 31/4418

US Classification:

51425301, 5462704, 514342, 548203, 514365, 546 1, 514277, 546209, 514326, 544360, 544370, 51425406, 5462701

Abstract:

The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.